These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33858190)

  • 41. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
    Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
    Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
    Burnett AK; Russell NH; Hills RK; Knapper S; Freeman S; Huntly B; Clark RE; Thomas IF; Kjeldsen L; McMullin MF; Drummond M; Kell J; Spearing R
    J Clin Oncol; 2021 Mar; 39(8):890-901. PubMed ID: 33356418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
    Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
    J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
    Zeidner JF; Foster MC; Blackford AL; Litzow MR; Morris LE; Strickland SA; Lancet JE; Bose P; Levy MY; Tibes R; Gojo I; Gocke CD; Rosner GL; Little RF; Wright JJ; Doyle LA; Smith BD; Karp JE
    Haematologica; 2015 Sep; 100(9):1172-9. PubMed ID: 26022709
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
    Penel-Page M; Plesa A; Girard S; Marceau-Renaut A; Renard C; Bertrand Y
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28305. PubMed ID: 32307866
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
    Amadori S; Suciu S; Stasi R; Salih HR; Selleslag D; Muus P; De Fabritiis P; Venditti A; Ho AD; Lübbert M; Thomas X; Latagliata R; Halkes CJ; Falzetti F; Magro D; Guimaraes JE; Berneman Z; Specchia G; Karrasch M; Fazi P; Vignetti M; Willemze R; de Witte T; Marie JP
    J Clin Oncol; 2013 Dec; 31(35):4424-30. PubMed ID: 24127442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
    Bourne G; Diebold K; Espinoza-Gutarra M; Al-Kadhimi Z; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R; Jamy O
    Leuk Res; 2024 Apr; 139():107467. PubMed ID: 38460432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
    Castaigne S; Pautas C; Terré C; Raffoux E; Bordessoule D; Bastie JN; Legrand O; Thomas X; Turlure P; Reman O; de Revel T; Gastaud L; de Gunzburg N; Contentin N; Henry E; Marolleau JP; Aljijakli A; Rousselot P; Fenaux P; Preudhomme C; Chevret S; Dombret H;
    Lancet; 2012 Apr; 379(9825):1508-16. PubMed ID: 22482940
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
    Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
    Röllig C; Schliemann C; Ruhnke L; Fransecky L; Heydrich BN; Hanoun M; Noppeney R; Schäfer-Eckart K; Wendelin K; Mikesch JH; Middeke JM; Reimann M; Fiebig F; Zukunft S; Wermke M; Serve H; Platzbecker U; Müller-Tidow C; Baldus CD; Bornhäuser M
    Br J Haematol; 2024 Jun; 204(6):2254-2258. PubMed ID: 38593353
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine.
    Brethon B; Auvrignon A; Cayuela JM; Lapillonne H; Leverger G; Baruchel A
    Haematologica; 2006 Mar; 91(3):419-21. PubMed ID: 16531270
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.
    Kell J
    Expert Rev Anticancer Ther; 2016; 16(4):377-82. PubMed ID: 26942450
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone.
    Singh A; Thota S; Bradley T; Griffiths EA; Faber MG; Sadek S; Przespolewski A; Thompson JE; Baron J; Cronin T; Attwood K; Madarang EC; Watts J; Wang ES
    Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):613-620. PubMed ID: 34031004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience.
    Açar İH; Guvenc B
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984499
    [No Abstract]   [Full Text] [Related]  

  • 56. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
    Aplenc R; Alonzo TA; Gerbing RB; Lange BJ; Hurwitz CA; Wells RJ; Bernstein I; Buckley P; Krimmel K; Smith FO; Sievers EL; Arceci RJ;
    J Clin Oncol; 2008 May; 26(14):2390-3295. PubMed ID: 18467731
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
    Gottardi M; Sperotto A; Ghelli Luserna Di Rorà A; Padella A; Cangini D; Giannini MB; Simonetti G; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):395-410. PubMed ID: 32955828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
    Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.
    Walter RB; Medeiros BC; Powell BL; Schiffer CA; Appelbaum FR; Estey EH
    Haematologica; 2012 May; 97(5):739-42. PubMed ID: 22133771
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
    Stone RM; Moser B; Sanford B; Schulman P; Kolitz JE; Allen S; Stock W; Galinsky I; Vij R; Marcucci G; Hurd D; Larson RA;
    Leuk Res; 2011 Mar; 35(3):329-33. PubMed ID: 20688393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.